These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 19229801)

  • 1. Nephrogenic systemic fibrosis.
    Vosshenrich R; Reimer P
    Vasa; 2009 Feb; 38(1):31-8. PubMed ID: 19229801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue.
    Wiginton CD; Kelly B; Oto A; Jesse M; Aristimuno P; Ernst R; Chaljub G
    AJR Am J Roentgenol; 2008 Apr; 190(4):1060-8. PubMed ID: 18356456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nephrogenic systemic fibrosis: review of 370 biopsy-confirmed cases.
    Zou Z; Zhang HL; Roditi GH; Leiner T; Kucharczyk W; Prince MR
    JACC Cardiovasc Imaging; 2011 Nov; 4(11):1206-16. PubMed ID: 22093272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Revisiting nephrogenic systemic fibrosis in 6 kidney transplant recipients: a single-center experience.
    Lemy AA; del Marmol V; Kolivras A; High WA; Matos C; Laporte M; Nortier JL
    J Am Acad Dermatol; 2010 Sep; 63(3):389-99. PubMed ID: 20619488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nephrogenic systemic fibrosis: history and epidemiology.
    Thomsen HS
    Radiol Clin North Am; 2009 Sep; 47(5):827-31, vi. PubMed ID: 19744597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nephrogenic systemic fibrosis: risk factors and incidence estimation.
    Sadowski EA; Bennett LK; Chan MR; Wentland AL; Garrett AL; Garrett RW; Djamali A
    Radiology; 2007 Apr; 243(1):148-57. PubMed ID: 17267695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy: a primer for radiologists.
    Prasad SR; Jagirdar J
    J Comput Assist Tomogr; 2008; 32(1):1-3. PubMed ID: 18303280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nephrogenic systemic fibrosis: pathogenesis, diagnosis, and therapy.
    Kribben A; Witzke O; Hillen U; Barkhausen J; Daul AE; Erbel R
    J Am Coll Cardiol; 2009 May; 53(18):1621-8. PubMed ID: 19406336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The evolution of osseous metaplasia in localized cutaneous nephrogenic systemic fibrosis: a case report.
    Wiedemeyer K; Kutzner H; Abraham JL; Thakral C; Carlson JA; Tran TA; Hausser I; Hartschuh W
    Am J Dermatopathol; 2009 Oct; 31(7):674-81. PubMed ID: 19633532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nephrogenic systemic fibrosis is found only among gadolinium-exposed patients with renal insufficiency: a case-control study from Denmark.
    Elmholdt TR; Pedersen M; Jørgensen B; Søndergaard K; Jensen JD; Ramsing M; Olesen AB
    Br J Dermatol; 2011 Oct; 165(4):828-36. PubMed ID: 21692765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue gadolinium deposition in renally impaired rats exposed to different gadolinium-based MRI contrast agents: evaluation with inductively coupled plasma mass spectrometry (ICP-MS).
    Sato T; Ito K; Tamada T; Kanki A; Watanabe S; Nishimura H; Tanimoto D; Higashi H; Yamamoto A
    Magn Reson Imaging; 2013 Oct; 31(8):1412-7. PubMed ID: 23643157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent topics related to nephrogenic systemic fibrosis associated with gadolinium-based contrast agents.
    Kitajima K; Maeda T; Watanabe S; Ueno Y; Sugimura K
    Int J Urol; 2012 Sep; 19(9):806-11. PubMed ID: 22571387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transmetallation and gadolinium: do low iron stores prevent the development of nephrogenic systemic fibrosis in high-risk end-stage renal disease patients?
    Panesar M; Boateng F; Patel SS; Masood SF; Mahajan P; Patel N; Murray B
    Hemodial Int; 2010 Jul; 14(3):289-94. PubMed ID: 20662951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Nephrogenic systemic fibrosis and use of MR contrast media].
    Christiansen RE; Sviland L; Sekse I; Svarstad E
    Tidsskr Nor Laegeforen; 2009 Jan; 129(3):180-2. PubMed ID: 19180161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nephrogenic systemic fibrosis: report of an additional case with granulomatous inflammation.
    Wilford C; Fine JD; Boyd AS; Sanyal S; Abraham JL; Kantrow SM
    Am J Dermatopathol; 2010 Feb; 32(1):71-5. PubMed ID: 19940755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nephrogenic systemic fibrosis-like effects of magnetic resonance imaging contrast agents in rats with adenine-induced renal failure.
    Fretellier N; Bouzian N; Parmentier N; Bruneval P; Jestin G; Factor C; Mandet C; Daubiné F; Massicot F; Laprévote O; Hollenbeck C; Port M; Idée JM; Corot C
    Toxicol Sci; 2013 Jan; 131(1):259-70. PubMed ID: 22977165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nephrogenic systemic fibrosis: a case series suggesting gadolinium as a possible aetiological factor.
    Moreno-Romero JA; Segura S; Mascaró JM; Cowper SE; Julià M; Poch E; Botey A; Herrero C
    Br J Dermatol; 2007 Oct; 157(4):783-7. PubMed ID: 17627792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients.
    Abujudeh HH; Kaewlai R; Kagan A; Chibnik LB; Nazarian RM; High WA; Kay J
    Radiology; 2009 Oct; 253(1):81-9. PubMed ID: 19709997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of extracellular gadolinium-based MRI contrast agents and the risk of nephrogenic systemic fibrosis.
    Heverhagen JT; Krombach GA; Gizewski E
    Rofo; 2014 Jul; 186(7):661-9. PubMed ID: 24477507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue gadolinium deposition and fibrosis mimicking nephrogenic systemic fibrosis (NSF)-subclinical nephrogenic systemic fibrosis?
    Boyd AS; Sanyal S; Abraham JL
    J Am Acad Dermatol; 2010 Feb; 62(2):337-42. PubMed ID: 19939504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.